LXRepair provides a new approach to personalized cancer medicine by developing functional diagnostics based on a unique breakthrough technology: DNA Repair Enzyme Signature analysis.
The French Atomic Energy Commission (CEA) has been studying the impact of radiation on DNA for several decades. This research has resulted in a good understanding of the essential DNA repair mechanisms.
Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.
LXRepair is a CEA spin-off building on over 25 years' research into the science behind DNA repair mechanisms and in vitro diagnostics for cancer.